Elevance Health (NYSE:ELV) received 6 somewhat bullish ratings from analysts over the last three months, with an updated average 12-month price target of $563.17, marking a 0.66% increase from the previous target. The company, a leading U.S. health insurer and the largest provider of Blue Cross Blue Shield branded coverage, reported a revenue growth of 6.81% as of December 31, 2023, and outperformed industry averages in net margin, ROE, and ROA, despite a high debt-to-equity ratio.